22 completed, 12 recruiting, 6 unknown. 13 Phase 3, 12 Phase 1, 6 Not applicable, 5 Phase 2, 4 Phase 4.
Follow Valenta Pharm JSC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Food-Effect, Single and Multiple Dose Pharmacokinetics, Safety and Tolerability Study of 4-MUST, 128 mg, Tablets in Healthy Volunteers 4-MUST - Chronic Cholecystitis, Biliary Dyskinesia | Phase 1 | Recruiting | Valenta Pharm JSC | 45 | 2026-01-26 | 2026-06-15 |
| Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Chronic Cholecystitis and Biliary Dyskinesia 4-MUST, Placebo - Chronic Cholecystitis, Biliary Dyskinesia | Phase 3 | Recruiting | Valenta Pharm JSC | 300 | 2025-12-12 | 2026-05-19 |
| Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers. Trimedat® - Irritable Bowel Syndrome, Gallstone Disease | Phase 1 | Recruiting | Valenta Pharm JSC | 36 | 2025-11-06 | 2026-02-19 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections. Ingavirin Forte, 90 mg + 5 mg, Capsules, Ingavirin Forte, 90 mg + 10 mg, Capsules, Ingavirin Forte, 90 mg + 20 mg, Capsules - Influenza, Acute Respiratory Viral Infection | Phase 2 | Recruiting | Valenta Pharm JSC | 300 | 2025-10-24 | 2026-02-19 |
| Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions. Ingavirin forte, capsules, 90 mg + 20 mg, Ingavirin, capsules, 90 mg - Influenza, Acute Respiratory Viral Infections | Phase 1 | Recruiting | Valenta Pharm JSC | 36 | 2025-07-11 | 2026-06-12 |
| Study of the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of Ingavirin Forte, Capsules, Folliwing Single and Subsequent Multiple Oral Administration in Healthy Volunteers Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 5 mg, Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 10 mg, Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 20 mg - Influenza, Viral Respiratory Infection | Phase 1 | Recruiting | Valenta Pharm JSC | 36 | 2025-01-13 | 2025-07-08 |
| Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders Ranquilon, Afobazole - Anxiety, Neurasthenia | Phase 4 | Recruiting | Valenta Pharm JSC | 250 | 2025-01-13 | 2025-07-08 |
| Safety, Tolerability, and Pharmacokinetic Profile of Grammidin, a Metered Dose Topical Spray in Healthy Volunteers Grammidin neo, Grammidin, a metered dose topical spray - Pharyngitis | Phase 1 | Recruiting | Valenta Pharm JSC | 24 | 2024-12-10 | 2025-07-10 |
| Safety, Tolerability, and Pharmacokinetic Profile of Grammidin With Anesthetic, a Metered Dose Topical Spray in Healthy Volunteers Grammidin with anesthetic neo, Grammidin with anesthetic, a metered dose topical spray - Pharyngitis | Phase 1 | Recruiting | Valenta Pharm JSC | 24 | 2024-12-09 | 2025-07-10 |
| Study to Evaluate the Efficacy and Safety of Different Doses of Graminidin With Anesthetic, a Metered Dose Topical Spray, in the Treatment of Acute Infectious and Inflammatory Pharyngeal Diseases Compared With Drug Septolete Total, Lozenges Grammidin with anesthetic, Septolete Total - Pharyngitis Acute, Pharyngitis | Phase 2 | Recruiting | Valenta Pharm JSC | 300 | 2024-11-14 | 2025-07-10 |
| Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia 4-MUST, Placebo - Chronic Cholecystitis, Biliary Dyskinesia | Phase 2 | Recruiting | Valenta Pharm JSC | 300 | 2024-10-17 | 2025-07-11 |
| Pharmacokinetics and Bioequivalence of Aterixen 100 mg Tablets and Aterixen 100 mg Film-coated Tablets in Healthy Volunteers Aterixen - Viral Infection COVID-19 | Not applicable | Unknown | Valenta Pharm JSC | 36 | 2024-06-15 | 2024-03-29 |
| Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers Antareit - Heartburn, Acid-dependent Diseases of the Gastrointestinal Tract | Not applicable | Unknown | Valenta Pharm JSC | 50 | 2024-04-25 | 2024-07-22 |
| Food Effect on the Bioavailability of 4-MUST, Tablets, 128 mg 4-MUST, 2 tablets, fasted, 4-MUST, 2 tablets, after meals - Cholecystitis | Phase 1 | Unknown | Valenta Pharm JSC | 24 | 2024-03-19 | 2024-04-02 |
| Pharmacokinetics and Bioequivalence of Doxylamine+Pyridoxine and Diclectin Under Fed Conditions in Healthy Volunteers Doxylamine + Pyridoxine, Diclectin - Nausea | Phase 1 | Completed | Valenta Pharm JSC | 28 | 2024-02-27 | 2025-07-11 |
| Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo Vespireit, Arlevert - Vertigo, Autonomic Dysfunction | Phase 4 | Recruiting | Valenta Pharm JSC | 160 | 2024-01-24 | 2025-06-15 |
| Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory Viral Infections Ingavirin®, Placebo - Influenza, Human, Acute Respiratory Infection | Phase 4 | Unknown | Valenta Pharm JSC | 80 | 2023-12-19 | 2024-04-01 |
| Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral Infections XC8, Placebo - Acute Respiratory Infection | Phase 3 | Unknown | Valenta Pharm JSC | 252 | 2023-12-04 | 2024-04-23 |
| Safety, Tolerability and Pharmacokinetics of 4-MUST, Tablets, 128 mg (Valenta Pharm JSC) During Single and Multiple Oral Administration in Healthy Volunteers 4-MUST, 1 tablet, 4-MUST, 2 tablets, 4-MUST, 3 tablets - Cholecystitis | Phase 1 | Unknown | Valenta Pharm JSC | 42 | 2023-12-04 | 2024-03-18 |
| A Study of the Efficacy and Safety of Ranquilon Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders Ranquilon, Placebo - Anxiety, Neurasthenia | Phase 3 | Completed | Valenta Pharm JSC | 220 | 2022-10-12 | 2023-07-27 |
Showing 20 of 40. Sign in to see all of them.
Influenza, Human (15) · Common Cold (9) · Biliary Dyskinesia (4) · Virus Diseases (4) · Pharyngitis (3) · Adjustment Disorders (2) · Anxiety Disorders (2) · COVID-19 (2) · Cholecystitis (2) · Duodenal Ulcer (2) · Heartburn (2) · Nausea (2) · Neurasthenia (2) · Primary Dysautonomias (2) · Vertigo (2)
pentanedioic acid imidazolyl ethanamide (10) · XC221 (3) · Anesthetics (2) · Cetylpyridinium (2) · GB-115 (2) · Gramicidin (2) · benoxinate (2) · dicyclomine, doxylamine, pyridoxine drug combination (2) · 2-((2-morpholino)ethylthio)-5-ethoxybenzimidazole (1) · Benzydamine (1) · Buspirone (1) · Capsules (1) · Doxylamine (1) · Postprandial Period (1) · Pyridoxine (1)
Russia (40)
Ekaterina Zakharova, MD, PhD (5) · Yuriy V. Lobzin, MD, PhD (1)